CytoSorbents Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $9.200M Miss $10.100M Estimate

Like
Comment
Favorite

CytoSorbents Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $9.200M Miss $10.100M Estimate

Benzinga03-31

CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. The company reported quarterly sales of $9.200 million which missed the analyst consensus estimate of $10.100 million by 8.91 percent. This is a 5.75 percent increase over sales of $8.700 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

09:38
Beyout Investment Group Holding - Unit Signs Contract to Sell a Land for 3.3 Mln Dinars
09:28
Zijin Mining Says Unit Norton Gold Fields Completed Sale of Its Unit Bullabuilding Gold to Minerals 260
09:04
Indonesia to Pursue Diplomacy and Negotiations to Find Mutual Beneficial Solution for Both Countries, Senior Econ Minister Says
09:04
Indonesia Will Not Take Retaliatory Measures Against US Tariff, Senior Econ Minister Says
08:13
Misr El Gadida FY Cash Dividend at EGP 1.3347 per Share

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2524972571?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-04-01 04:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524972571","market":"hk","top_or_hot":-1,"title":"CytoSorbents Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $9.200M Miss $10.100M Estimate","media":"Benzinga","content":"<html><body><p>CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent.  The company reported quarterly sales of $9.200 million which missed the analyst consensus estimate of $10.100 million by 8.91 percent.  This is a 5.75 percent increase over sales of $8.700 million the same period last year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoSorbents Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $9.200M Miss $10.100M Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoSorbents Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $9.200M Miss $10.100M Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-04-01 04:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent.  The company reported quarterly sales of $9.200 million which missed the analyst consensus estimate of $10.100 million by 8.91 percent.  This is a 5.75 percent increase over sales of $8.700 million the same period last year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTSO","symbol_name":"Cytosorbents Corporation","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/25/03/44571485/cytosorbents-q4-2024-adj-eps-0-03-beats-0-06-estimate-sales-9-200m-miss-10-100m-estimate","article_id":"2524972571","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524972571","pubTimestamp":1743452513,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent.  The company reported quarterly sales of $9.200 million which missed the","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CTSO":"Cytosorbents Corporation"},"translate_title":"细胞吸附剂2024年第四季度调整后每股收益(0.03)美元超出预期(0.06)美元，销售额920万美元低于预期1010万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTSO":0.9},"content_text":"CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent.  The company reported quarterly sales of $9.200 million which missed the analyst consensus estimate of $10.100 million by 8.91 percent.  This is a 5.75 percent increase over sales of $8.700 million the same period last year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}